Simona Soverini
Simona Soverini
Assistant Professor, University of Bologna
Verified email at unibo.it
TitleCited byYear
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ...
Blood 122 (6), 872-884, 2013
15142013
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL …
T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ...
Blood 108 (1), 28-37, 2006
12232006
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
S Soverini, S Colarossi, A Gnani, G Rosti, F Castagnetti, A Poerio, ...
Clinical Cancer Research 12 (24), 7374-7379, 2006
5092006
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European …
S Soverini, A Hochhaus, FE Nicolini, F Gruber, T Lange, G Saglio, F Pane, ...
Blood 118 (5), 1208-1215, 2011
4772011
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression …
S Soverini, G Martinelli, G Rosti, S Bassi, M Amabile, A Poerio, B Giannini, ...
Journal of clinical oncology 23 (18), 4100-4109, 2005
4182005
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase
T Hughes, G Saglio, S Branford, S Soverini, DW Kim, MC Müller, ...
Journal of Clinical Oncology 27 (25), 4204, 2009
3252009
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
R Foà, A Vitale, M Vignetti, G Meloni, A Guarini, MS De Propris, L Elia, ...
Blood 118 (25), 6521-6528, 2011
2812011
IKZF1 (Ikaros) Deletions in BCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative …
G Martinelli, I Iacobucci, CT Storlazzi, M Vignetti, F Paoloni, D Cilloni, ...
Journal of Clinical Oncology 27 (31), 5202-5207, 2009
2602009
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
G Rosti, F Palandri, F Castagnetti, M Breccia, L Levato, G Gugliotta, ...
Blood 114 (24), 4933-4938, 2009
2382009
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute lymphoblastic leukemia …
I Iacobucci, CT Storlazzi, D Cilloni, A Lonetti, E Ottaviani, S Soverini, ...
Blood 114 (10), 2159-2167, 2009
2042009
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
S Soverini, S Colarossi, A Gnani, F Castagnetti, G Rosti, C Bosi, S Paolini, ...
Haematologica 92 (3), 401-404, 2007
1972007
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study
M Baccarani, D Cilloni, M Rondoni, E Ottaviani, F Messa, S Merante, ...
haematologica 92 (9), 1173-1179, 2007
1952007
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma
PL Zinzani, A Pulsoni, A Perrotti, S Soverini, F Zaja, A De Renzo, S Storti, ...
Journal of clinical oncology 22 (13), 2654-2661, 2004
1812004
BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships
JS Khorashad, TW Kelley, P Szankasi, CC Mason, S Soverini, LT Adrian, ...
Blood 121 (3), 489-498, 2013
1742013
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with …
S Soverini, A Gnani, S Colarossi, F Castagnetti, E Abruzzese, S Paolini, ...
Blood 114 (10), 2168-2171, 2009
1702009
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous …
S Soverini, M Cavo, C Cellini, C Terragna, E Zamagni, D Ruggeri, ...
Blood 102 (5), 1588-1594, 2003
1452003
Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
S Soverini, C De Benedittis, KM Polakova, A Brouckova, D Horner, ...
Blood 122 (9), 1634-1648, 2013
1342013
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib
S Soverini, G Martinelli, M Amabile, A Poerio, M Bianchini, G Rosti, ...
Clinical chemistry 50 (7), 1205-1213, 2004
1262004
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new …
I Iacobucci, A Lonetti, F Messa, D Cilloni, F Arruga, E Ottaviani, S Paolini, ...
Blood 112 (9), 3847-3855, 2008
1242008
Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Baccarani, S Pileri, JL Steegmann, M Muller, S Soverini, M Dreyling, ...
Annals of oncology 23 (suppl_7), vii72-vii77, 2012
1212012
The system can't perform the operation now. Try again later.
Articles 1–20